Clinical and Immunopathogenetic aspects of sarcoidosis
No Thumbnail Available
Date
2021
Authors
Morar, Rajen
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Sarcoidosis is a multiorgan granulomatous condition of uncertain aetiology, in which
the lungs are commonly affected. The disorder comprises important inflammatory
along with immune components; however, the exact aetiology is unknown and the
immunopathogenesis is not completely understood. Due to its similarities, both
radiologically as well as clinically, and particularly in high tuberculosis (TB) burden
regions, sarcoidosis is regularly misdiagnosed as TB.
Variation in disease prognosis, progression, presentation and susceptibility have been
linked to various human leukocyte antigen (HLA) phenotypes, which are important in
antigen presentation and involved in mounting an immune response to foreign
antigens. Cell-mediated immunity play a central part in the sarcoidosis’
immunopathogenesis. Humoral immunity changes, such as polyclonal gammopathy,
presence of auto-antibodies, immunoglobulins, complement and immune complexes
in the granuloma of sarcoidosis suggests that humoral mechanisms may well have a
role in the pathogenesis. Micro-ribonucleic acids (microRNAs or miRNAs) are groups
of non-coding, small, single-stranded RNAs. Their key role is to mediate the post transcriptional silencing of target genes. The role of miRNAs has attracted attention,
both in pathogenesis and as biomarkers for many disorders, including sarcoidosis. In
sarcoidosis, the role of miRNAs is not well recognised, but their role is being unravelled
by many workers. Chitotriosidase is a chitinase enzyme that acts as protection against
nematodes, fungi, and insects which are chitin-containing pathogens. It is selectively
expressed by activated macrophages. Sarcoidosis’ pathogenesis is known to involve
activated macrophages through the release of various cytokines, chemokines and
enzymes.
Aims
The current research was conducted in order to analyse and review clinical features of
sarcoidosis patients in the South African population. Being a relatively uncommon
condition, this would add to the profile of patients from other studies conducted in South
Africa. In addition, HLA Class I along with Class II antigens in sarcoidosis patients were
evaluated. Serum immunoglobulin (Ig) G subclass levels in newly diagnosed cases
with sarcoidosis were assessed, noting changes in antibody levels in corticosteroid treated patients and those undergoing spontaneous clinical response. The serum
expression of approximately 800 miRNAs in sarcoidosis patients were compared with
race-, age- as well as gender-matched healthy controls. Analysis of serum
chitotriosidase activity in sarcoidosis and TB patient cohort, both granulomatous
ailments of differing aetiology, was undertaken and compared with controls.
Methods
A five-year investigation was conducted among 102 patients with sarcoidosis attending
the pulmonology services of the Charlotte Maxeke Johannesburg Academic Hospital.
HLA-A, B, C (Class I) along with HLA-DQB1 and DRB1 (Class II) antigen typing in 51
patients from this cohort, was prospectively carried out by polymerase chain reaction
(PCR), utilising sequence specific primers. These antigens were compared with 63
healthy control subjects. Serum IgG subclasses levels were assessed prospectively,
both before and after treatment, or in cases with spontaneous recovery, in 17 newly
diagnosed cases of sarcoidosis, using a laser nephelometric method with appropriate
test kits. The RNA was extracted from stored plasma samples utilising the “QIAGEN
miRNeasy Mini Kit®” and concentrated using a salt-ethanol precipitation. The RNA
extracted was analysed using an nCounter® miRNA human v3 expression assay.
Twelve samples (6 patient and 6 matched controls) were analysed. Data were
analysed using the nSolver™ Analysis Software. Chitotriosidase activity was
prospectively assayed in serum of 12 biopsy-proven sarcoidosis cases before
treatment, 9 sarcoidosis patients after treatment, 10 confirmed pulmonary tuberculosis
patients prior to treatment, and in 12 healthy controls. Plasma chitotriosidase activity
was analysed utilising “4-methylumbelliferyl-β-D-N, N', N″-triacetylchitotriose” as a
substrate.
Results
Out of 102 sarcoidosis patients, 59 were Black, 28 Indian, eight White and seven
Coloured (mixed race). There were 69 females (67.6%) and 33 (32.4%) males. Majority
of patients were non-smokers (85.3%). The group’s mean age was 44.6 years.
Hypertension (32.4%), renal dysfunction (creatinine > 104 µmol/L) (19.5%), obesity
(17.6%), diabetes mellitus (15.7%), asthma (11.8%), and gastro-oesophageal reflux
(11.8%) were the most prevalent associated chronic comorbid diseases. Indian
patients had significantly more dyslipidaemia than Black patients (p = 0.02). Almost
17% of patients had been treated for tuberculosis, based on the chest radiograph, prior
to the diagnosis of sarcoidosis. Two cases developed active TB whilst being treated
with corticosteroids for sarcoidosis. Four Black patients contracted human
immunodeficiency virus (HIV) infection whilst on treatment for sarcoidosis. The salient
clinical manifestations were dry cough, the commonest presenting symptom in 82.4%,
dyspnoea in 53.9%, cutaneous lesions, other than erythema nodosum, in 33.3%, and
on lung examination crackles were noted in 37.3% of patients. The majority (48%) of
patients had stage II chest radiographic changes. Cutaneous biopsies (28.4%),
transbronchial lung biopsies (25.5%) and biopsies of mediastinal lymph nodes via
mediastinoscopy (25.5%) were the most frequent sites for confirming granulomatous
inflammation. Blacks were more likely to have non-erythema nodosum dermatological
manifestations at presentation. In Blacks 67.8% had an elevated ACE level compared
with 32.1%, 50% and 14.3% in Indians, Whites and Coloureds respectively. The mean
ACE level was higher in Blacks than in Indians (157 vs. 58 IU/L). The initial mean
serum calcium was elevated (> 2.5 mmol/L) in 22.7% of cases, the highest incidence
being in Whites (37%). Raised gamma-glutamyl transferase (GGT) (> 78 IU/L) and
alkaline phosphatase (AP) (> 128 IU/L) were observed in 31.8% and 21.6% of patients,
respectively. Elevated creatinine (> 104 μmol/L) was seen in 19.5% of patients; Whites
having the highest incidence of renal dysfunction at 37%. Overall, 21.2% of patients
had obstructive airways disease on lung function testing. Systemic corticosteroids
were indicated in 87.3% of patients and the relapse rate was 60.7%.
HLA class I along with class II phenotype analysis in 51 sarcoidosis patients found
significant increased levels of HLA B15, C4, C7, C12, C15, C16, C17, DQ3, DR8 and
DR11. A significant negative (protective) connotation with HLA A9, A28, B12, B17 and
DR2 was observed.
In the IgG subclasses study, there were 17 Black patients of which six were men and
11 women. The mean age was 44 years (range 23-60 years). Raised initial IgG1 levels
were noted in 10 patients, IgG3 levels in 8, IgG2 levels in 4, and IgG4 in 2 patients.
The mean IgG1 and IgG3 levels were significantly raised above normal control values.
Fourteen patients were treated with corticosteroids with good clinical response, and
three, in whom there was no indication for therapy, were asymptomatic. On follow-up
there was a significant decrease in IgG subclass levels toward normal. IgG1 levels
returned to normal in almost all cases, and IgG3 remained raised in two cases. The
mean levels of IgG1 and IgG3 decreased significantly, as did the levels of IgG2.
Regarding miRNA, one pair of results was excluded due to cellular RNA contamination.
Therefore, five patients and matched control samples were analysed. After excluding
miRNAs that were below background levels, 145 miRNAs could be analysed. On
applying a Bonferroni correction, the only miRNA that was significantly different was
miRNA let-7a-5p, which was significantly overexpressed (141-fold change; p < 0.0003)
in sarcoidosis cases compared with controls. Of the 145 miRNAs, many had been
differentially expressed among patients compared with controls, although not reaching
statistical significance.
Serum chitotriosidase activity has been shown to be significantly greater in sarcoidosis
cases, both before (p < 0.0001) and after treatment (p < 0.0039), compared with
controls. Sarcoidosis cases had significantly higher chitotriosidase levels than TB
cases and chitotriosidase activity decreased with treatment in sarcoidosis. While in
patients with TB chitotriosidase activity was noted to be lower than in sarcoidosis, it
was higher than in controls.
Conclusions
In South Africa, sarcoidosis is often misdiagnosed as TB. In this study, the most
frequent sites for biopsy for histological confirmation were skin, mediastinal lymph
node and transbronchial lung biopsy. Comorbid illnesses were common and should be
screened for and treated promptly to improve quality of life. Most of the cases in this
cohort with sarcoidosis had an indication for treatment with corticosteroids.
The HLA study is unique to South African patients and indicates that genetic influences
may play a significant part in the potential aetiology of sarcoidosis. There are some
HLA subtypes that may be a predisposition to the development of sarcoidosis and other
HLA subtypes that may be protective.
IgG subclasses, mainly IgG1 as well as IgG3 were elevated in a substantial proportion
of sarcoidosis cases initially, and reduced with corticosteroid therapy and in those
patients with spontaneous clinical resolution. These IgG subclass responses may be
due to protein antigens that usually trigger B-cells leading to class switching to IgG1
and IgG3 via T-cell help through MHC-class II expression. Therefore, IgG subclasses
may act as opsonins, bind to microbes and facilitate phagocytosis in sarcoidosis.
This is the first study of differentially expressed miRNAs in serum of sarcoidosis cases
and matched healthy controls in South Africa. The results obtained indicate that
miRNAs may have a role in sarcoidosis pathogenesis involved in regulating
inflammatory pathways. Whether these molecules have diagnostic or prognostic
implications, further research in larger cohorts are required.
This is the first study of chitotriosidase activity analysis in sera of sarcoidosis and TB
cases in South Africa. The processes that result in the increase of chitotriosidase
activity are not yet understood, but in reaction to macrophage activation, this enzyme
may be involved when there are chitin containing organisms implicated in the disease
pathogenesis. To validate these findings, further studies with higher patient numbers
are required. It remains to be determined if chitotriosidase is a diagnostic or predictive
marker in sarcoidosis
Description
A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy to the Faculty of Health Sciences, School of Medicine, University of the Witwatersrand, Johannesburg, 2021